Cyfuse Biomedical K.K. (4892.T)
JPY 982.0
(-0.2%)
JPY 982.0
(-0.2%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.21 Billion JPY | -12.47% |
| 2022 | 4.81 Billion JPY | 81.97% |
| 2021 | 2.64 Billion JPY | 20.49% |
| 2020 | 2.19 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.9 Billion JPY | -7.38% |
| 2024 Q2 | 3.84 Billion JPY | -1.51% |
| 2023 Q3 | 4.17 Billion JPY | -4.89% |
| 2023 FY | 4.21 Billion JPY | -12.47% |
| 2023 Q4 | 4.21 Billion JPY | 1.02% |
| 2023 Q2 | 4.38 Billion JPY | -4.53% |
| 2023 Q1 | 4.59 Billion JPY | -4.58% |
| 2022 FY | 4.81 Billion JPY | 81.97% |
| 2022 Q4 | 4.81 Billion JPY | 77.02% |
| 2022 Q3 | 2.72 Billion JPY | 0.0% |
| 2021 FY | 2.64 Billion JPY | 20.49% |
| 2020 FY | 2.19 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 36.57 Billion JPY | 88.476% |
| Takeda Pharmaceutical Company Limited | 15108.79 Billion JPY | 99.972% |
| Sumitomo Pharma Co., Ltd. | 907.5 Billion JPY | 99.536% |
| Shionogi & Co., Ltd. | 1416.91 Billion JPY | 99.703% |
| Wakamoto Pharmaceutical Co.,Ltd. | 15.42 Billion JPY | 72.668% |
| Nippon Shinyaku Co., Ltd. | 263.4 Billion JPY | 98.4% |
| Kaken Pharmaceutical Co., Ltd. | 171.62 Billion JPY | 97.544% |
| Eisai Co., Ltd. | 1393.79 Billion JPY | 99.698% |
| Morishita Jintan Co., Ltd. | 17.18 Billion JPY | 75.471% |
| Hisamitsu Pharmaceutical Co., Inc. | 328.77 Billion JPY | 98.718% |
| Mochida Pharmaceutical Co., Ltd. | 158.8 Billion JPY | 97.346% |
| Fuso Pharmaceutical Industries,Ltd. | 76.46 Billion JPY | 94.488% |
| Nippon Chemiphar Co., Ltd. | 49.54 Billion JPY | 91.493% |
| Tsumura & Co. | 428.25 Billion JPY | 99.016% |
| Kissei Pharmaceutical Co., Ltd. | 260.92 Billion JPY | 98.385% |
| Torii Pharmaceutical Co., Ltd. | 133.43 Billion JPY | 96.841% |
| Towa Pharmaceutical Co., Ltd. | 430.65 Billion JPY | 99.021% |
| Fuji Pharma Co., Ltd. | 85.33 Billion JPY | 95.061% |
| Zeria Pharmaceutical Co., Ltd. | 150.53 Billion JPY | 97.2% |
| KYORIN Holdings, Inc. | 177.67 Billion JPY | 97.628% |
| Taiko Pharmaceutical Co.,Ltd. | 15.04 Billion JPY | 71.987% |
| Daito Pharmaceutical Co.,Ltd. | 77.7 Billion JPY | 94.576% |
| SymBio Pharmaceuticals Limited | 15.35 Billion JPY | 72.546% |
| MedRx Co., Ltd | 2.05 Billion JPY | -105.4% |
| Mizuho Medy Co.,Ltd. | 18.94 Billion JPY | 77.756% |
| Solasia Pharma K.K. | 2.55 Billion JPY | -65.287% |
| Modalis Therapeutics Corporation | 2.02 Billion JPY | -108.044% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 93.31 Billion JPY | 95.483% |
| Sawai Group Holdings Co., Ltd. | 382.02 Billion JPY | 98.897% |
| Toho Holdings Co., Ltd. | 773.42 Billion JPY | 99.455% |
| Koa Shoji Holdings Co.,Ltd. | 32 Billion JPY | 86.83% |